natgillin/translations-raw huggingface dataset:
For the treatment of prostate cancer, TAXOTERE is administered in combination with prednisone or prednisolone.
Za zdravljenje raka prostate se zdravilo TAXOTERE lahko uporablja v kombinaciji s prednizonom ali prednizolonom.
For the treatment of pulmonary
indromom in adrenalno
For the treatment of pulmonary arterial hypertension
Za zdravljenje pljučne
For the treatment of pulmonary arterial hypertension
Za zdravljenje pljučne arterijske hipertenzije
For the treatment of sarcoptic mange (Sarcoptes scabiei).
Za zdravljenje garjavosti Sarcoptes scabiei.
For the treatment of schizophrenia, there were three main short-term studies lasting four to six weeks, which involved 1,203 adults and compared Abilify tablets with placebo (a dummy treatment).
Pri zdravljenju shizofrenije so zdravilo Abilify proučevali pri 1 203 odraslih v treh kratkotrajnih študijah, ki so trajale od štiri do šest tednov in v katerih so tablete zdravila Abilify primerjali s placebom (zdravilom brez zdravilne učinkovine).
For the treatment of skin and soft tissue abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis,  haemolytic Streptococci and/or Staphylococcus pseudintermedius.
Za zdravljenje abscesov in ran kože in mehkega tkiva povezanih z okužbo s Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis, -hemolitičnimi Streptococci in/ali s Staphylococcus pseudintermedius.
For the treatment of skin and soft tissue abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis,  haemolytic Streptococci and/or Staphylococcus pseudintermedius.
Za zdravljenje abscesov in ran kože in mehkega tkiva povezanih z okužbo s Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis, -hemolitičnimi Streptococci.in/ali s Staphylococcus pseudintermedius.
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius,  haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida.
Za zdravljenje infekcije kože in mehkega tkiva vključno s piodermo, ranami in abscesi povezanimi s Staphylococcus pseudintermedius, -hemolitičnimi Streptococci, Escherichia coli in/ali Pasteurella multocida.
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, -haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida.
Za zdravljenje infekcije kože in mehkega tkiva vključno s piodermo, ranami in abscesi, povezanimi z okužbo s Staphylococcus pseudintermedius, -hemolitičnimi Streptococci, Escherichia coli in/ali Pasteurella multocida.
for the treatment of some cancers of the blood
za zdravljenje nekaterih krvnih rakov
For the treatment of SRD a field study was conducted in pigs with SRD comparing ZACTRAN to tildipirosin, another macrolide antibiotic.
Pri zdravljenju respiratorne bolezni prašičev so izvedli terensko študijo na prašičih z respiratorno boleznijo prašičev, v kateri so zdravilo ZACTRAN primerjali s tildipirozinom, drugim makrolidnim antibiotikom.
For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase- positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.
Za zdravljenje subkliničnega mastitisa pri kravah v obdobju laktacije, ki ga povzročajo grampozitivni koki, občutljivi na pirlimicin, vključno s stafilokoki kot so Staphylococcus aureus (penicilinaza pozitivni, penicilinaza negativni in koagulaza negativni stafilokoki), streptokoki, vključno Streptococcus agalctiae, Streptococcus dysgalactiae in Streptococcus uberis.
For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase- positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.
Za zdravljenje subkliničnega mastitisa pri kravah v obdobju laktacije, ki ga povzročajo grampozitivni koki, občutljivi na pirlimicin, vključno s stafilokoki kot so Staphylococcus aureus (penicilinaza pozitivni, penicilinaza negativni in koagulaza negativni stafilokoki), streptokoki, vključno Streptococcus agalctiae, Streptococcus dysgalactiae in Streptococcus uberis.
For the treatment of tick and flea infestations in cats.
Za zdravljenje infestacije s klopi in bolhami pri mačkah.
For the treatment of tick and flea infestations in cats.
Za zdravljenje infestacije z bolhami in klopi pri mačkah.
For the treatment of tick and flea infestations in dogs.
Za zdravljenje infestacije s klopi in bolhami na psih.
For the treatment of tick and flea infestations in dogs.
Za zdravljenje infestacije s klopi in bolhami pri psih.
For the treatment of tick and flea infestations in dogs.
Za zdravljenje infestacije z bolhami in klopi pri psih.
For the treatment of tick and flea infestations on dogs.
Za zdravljenje infestacije z bolhami in klopi na psih
For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus).
Zdravljenje infestacij s klopi (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus in Rhipicephalus sanguineus).
For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp.
Za zdravljenje infekcije urinarnega trakta povezane z okužbo z Escherichia coli in/ali Proteus spp.
For the treatment of urinary tract infections associated with Escherichia coli.
Za zdravljenje infekcije urinarnega trakta, povezane z okužbo s Escherichia coli.
For the treatment of vomiting, in combination with other supportive measures.
Za preprečevanje in zdravljenje bruhanja v kombinaciji z ostalimi veterinarskimi in podpornimi terapijami.
For the treatment of vomiting, in combination with other supportive measures.
Za zdravljenje bruhanja v kombinaciji z ostalimi podpornimi terapijami.
For the treatment of vulvar and vaginal atrophy, Senshio should only be initiated for symptoms that adversely affect quality of life e.g. dyspareunia and vaginal dryness.
Za zdravljenje vulvarne in vaginalne atrofije se lahko zdravilo Senshio uvede le zaradi simptomov, ki slabo vplivajo na kakovost življenja, npr. disparevnijo in suhost nožnice.
For the treatment of:
Za zdravljenje:
For the UPDRS, higher scores indicate greater severity of impairment
Pri lestvici UPDRS večji rezultati pomenijo hujšo okvaro.
For the use of sildenafil with the most potent CYP3A4 inhibitors, see section 4.3. Dose adjustments for sildenafil may be required when co-administered with CYP3A4 inducers (see section 4.5).
Za uporabo sildenafila skupaj z najmočnejšimi zaviralci encima CYP3A4 glejte poglavje 4.3. Morebiti bo potrebna prilagoditev odmerka sildenafila med sočasno uporabo z induktorji CYP3A4 (glejte poglavje 4.5).
For therapy of patients with relapsed or refractory Non-Hodgkin’s lymphoma not responding to rituximab
Za zdravljenje bolnikov z relapsnim ali neodizvnim ne–Hodgkinovim limfomom, ki se ne odziva na rituksimab
For these ADRs, an additional check of the frequency of the ADRs captured by the Phase II study algorithm was undertaken and, if the frequency of the ADRs in the Phase II study was higher than in the Phase III study, the event was included in the EU SmPC at the frequency it occurred in the Phase II study.
Za te neželene učinke so dodatno preverili pogostnost neželenih učinkov, zajetih z algoritmom študije faze II, in če je bila pogostnost neželenih učinkov v študiji faze II večja kot v študiji faze III, je bil neželeni učinek vključen v EU SmPC s pogostnostjo, s katero se je pojavljal v študiji faze II.
For these children the use of Diacomit will be done under the close supervision of the doctor.
Uporaba stiripentola pri teh otrocih poteka pod skrbnim zdravnikovim nadzorom.
For these conditions, the most common general side effect of Eliquis is bleeding which may be potentially life threatening and require immediate medical attention.
Za ta stanja velja, da so najpogostejši splošni neželeni učinek zdravila Eliquis krvavitve, ki so lahko smrtno nevarne in zahtevajo takojšnje zdravljenje.
For these dose cohorts, the combined 1-year survival rate was 88.1%.
Skupna stopnja 1-letnega preživetja za skupini bolnikov, ki sta prejemali ta dva odmerka, je bila 88,1%.
For these patients other treatment options should be considered.
Pri teh bolnikih je treba razmisliti o drugačnih možnostih zdravljenja.
For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended, and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4).
Zato kombinirana uporaba ciklosporina in takrolimusa ni priporočljiva; pri bolnikih, ki so prej dobivali ciklosporin, je treba takrolimus uporabiti previdno (glejte poglavji 4.2 in 4.4).
For these sedatives/hypnotics, dose
Odmerek teh sedativov/hipnotikov
For third occurrence
Tretji pojav
For this diagnosis, within 24 hours after the index PCI procedure, there had to be at least two CK-MB values  3 x the upper limit of normal; thus, validation by the CEC was not required.
Za to diagnozo sta morali biti v obdobju 24 ur po zadevnem perkutanem koronarnem posegu najmanj dve vrednosti CK-MB  3 x zgornji meji normalnih vrednosti.
For this dose, a different tablet strength is available.
Za ta odmerek so na voljo tablete različnih jakosti.
For this product, the effective dose resulting from an administered activity of 555-740 MBq is typically 8.88–11.84 mSv for a 70 kg individual.
Pri tem zdravilu, je učinkovita doza po dajanju 555-740 MBq aktivnosti, tipično 8,88-11,84 mSv za 70 kg težko osebo.
For this purpose the following classification has been used:
V ta namen smo uporabili naslednjo klasifikacijo:
For this purpose Urorec 4 mg hard capsules are available.
V ta namen je na voljo zdravilo Urorec 4 mg trde kapsule.
For this purpose, it is recommended that the RET mutation status be tested before starting treatment with Caprelsa.
Za ta namen se priporoča določitev statusa mutacije RET pred začetkom zdravljenja z zdravilom Caprelsa.
For this purpose, Opdivo is used on its own or together with a medicine called ipilimumab; a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread locally or to other parts of the body in patients who have previously been treated with other cancer medicines (chemotherapy); advanced renal cell carcinoma, a type of kidney cancer that has spread throughout the body and cannot be surgically removed.
Za ta namen se zdravilo Opdivo uporablja samostojno ali v kombinaciji z zdravilom, imenovanim ipilimumab; vrsto raka, imenovanega nedrobnocelični pljučni rak (NSCLC), ki se je razširil lokalno ali v druge dele telesa pri bolnikih, ki so se predhodno zdravili z drugimi zdravili za zdravljenje raka (kemoterapijo); napredovalim karcinomom ledvičnih celic, tj. vrste ledvičnega raka, ki se je razširil po telesu in ga ni mogoče kirurško odstraniti.
For this reason it is mandatory to use protective high quality (latex/nitrile) gloves in any direct contact with the radiopharmaceutical (vial/syringe) and with the patient.
V ta namen je obvezna uporaba zaščitnih visokokakovostnih rokavic (lateks/nitril) pri vsakem neposrednem stiku z radiofarmakom (viala/brizga) in z bolnikom.
For this reason it is very important that you tell your child’s doctor about any changes in their health.
Zato je zelo pomembno, da otrokovega zdravnika obvestite o vseh spremembah njegovega zdravja.
For this reason, and to reduce the risk of HIV transmission, barrier contraception (e.g., condoms) is recommended.
Iz tega razloga in zato, da bi zmanjšali nevarnost prenosa HIV, priporočamo uporabo mehanske kontracepcije (npr. kondoma).
For this reason, careful consideration should be given before deciding to switch a stabilized dog onto imepitoin from a different treatment.
Zato je treba skrbno pretehtati, preden se odločimo, da bomo stabiliziranemu psu drugo zdravilo zamenjali z imepitoinom.
For this reason, it is possible that potent CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the phamacokinetics of sitagliptin in patients with severe renal impairment or ESRD.
Zato je mogoče, da pri bolnikih s hudo ledvično okvaro ali končno ledvično odpovedjo močni zaviralci encima CYP3A4 (tj. ketokonazol, itrakonazol, ritonavir, klaritromicin) spremenijo farmakokinetiko sitagliptina.
For this reason, it is possible that potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the phamacokinetics of sitagliptin in patients with severe renal impairment or ESRD.
Zato je mogoče, da pri bolnikih s hudo ledvično okvaro ali končno ledvično odpovedjo močni zaviralci encima CYP3A4 (tj. ketokonazol, itrakonazol, ritonavir, klaritromicin) spremenijo farmakokinetiko sitagliptina.
For this reason, thaw the ampoules in clean water at 25–27 °C. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Ampule odmrzujte v čisti vodi pri 25-27 °C. V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
For this reason, thaw the ampoules in clean water at 25–27 °C. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Ampule odmrzujte v čisti vodi pri 25-27 °C. V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
For this reason, Xadago should not be used during pregnancy or by women of childbearing potential not practicing adequate contraception.
Zdravila Xadago se zato ne sme uporabljati pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
For this same reason Ravicti must not be used to treat acute hyperammonaemia as more rapidly acting treatments are needed in these cases.
Zaradi tega se zdravilo Ravicti ne sme uporabljati za zdravljenje akutne hiperamonemije, saj so v teh primerih potrebna hitrejša zdravljenja.
For this the piston must be completely pushed into the syringe (figure )
Za to mora biti bat do konca pritisnjen v brizgo (slika )
For this use, Opdivo is used on its own.
Za ta namen se zdravilo Opdivo uporablja samostojno.
For those patients failing therapy with Eviplera and who developed resistance to Eviplera cross resistance to other approved NNRTIs (etravirine, efavirenz, nevirapine) was generally seen.
Za bolnike, pri katerih zdravljenje z zdravilom Eviplera ni bilo uspešno in pri katerih se je pojavila rezistenca na zdravilo Eviplera, so praviloma opazili navzkrižno rezistenco na druge odobrene NNRTI (etravirin, efavirenz, nevirapin).
For those patients for which there are data, the survival rate at 1 year is 96.4 %.
Pri bolnikih, pri katerih so bili podatki na voljo, je bilo preživetje v enem letu 96,4 %.
For those patients who are not refractory, platelets is the first line treatment for Glanzmann’s thrombasthenia.
Pri bolnikih, ki niso refraktarni, so prva izbira zdravljenja Glanzmannove trombastenije trombociti.
For those patients who received asfotase alfa: 9/13 patients displayed persistent apparent catch-up height-gain as shown by movement over time to a higher percentile on CDC growth charts.
Za bolnike, ki so prejemali asfotazo alfa: 9 od 13 bolnikov je kazalo vztrajno navidezno dohitevanje pridobivanja višine, kot prikazuje gibanje v času, do višjih percentil na tablicah rasti CDC.
For those patients with serum bilirubin > ULN and/or ALT and AST > 3.5 times the ULN associated with alkaline phosphatase > 6 times the ULN, no dose- reduction can be recommended and docetaxel should not be used unless strictly indicated.
Pri bolnikih, ki imajo serumski bilirubin > ULN in/ali ALT in AST > 3,5-kratno ULN ter hkrati alkalno fosfatazo > 6-kratno ULN, ni mogoče priporočiti zmanjšanja odmerka; pri teh bolnikih se docetaksela ne sme uporabljati, če ni strogo indiciran.
For those patients with serum bilirubin >ULN and/or ALT and AST
Pri bolnikih, ki imajo serumski bilirubin > ULN in/ali ALT in AST
For those patients with serum bilirubin >ULN and/or ALT and AST >3.5 times the ULN associated with alkaline phosphatase >6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
Pri bolnikih, ki imajo serumski bilirubin > ZMNO in/ali ALT in AST > 3,5-kratno ZMRO ter hkrati alkalno fosfatazo > 6-kratno ZMRO, ni mogoče priporočiti zmanjšanja odmerka; pri teh bolnikih se docetaksel ne sme uporabljati, če ni izrecno indiciran.
For three days before Glybera treatment and for twelve weeks after, patients are given immunosuppressive treatment to reduce the reaction of the body’s immune system against the medicine.
Tri dni pred zdravljenjem z zdravilom Glybera in dvanajst tednov po njem je treba bolnikom dajati imunosupresivno terapijo, ki zmanjša reakcijo imunskega sistema telesa na zdravilo.
For three times a day take Lyrica once in the morning, once in the afternoon and once in the evening, at about the same time each day.
jemljete zdravilo Lyrica trikrat na dan, ga vzemite zjutraj, popoldne in zvečer, in sicer vsak dan ob približno istem času.
For three times a day take Pregabalin Mylan Pharma once in the morning, once in the afternoon and once in the evening, at about the same time each day.
Če jemljete zdravilo Pregabalin Mylan Pharma trikrat na dan, ga vzemite zjutraj, popoldne in zvečer, in sicer vsak dan ob približno istem času.
for thyroid problems
pri težavah s ščitnico
For ticagrelor 90 mg Cmax was 627 ng/ml and AUC was 6255 ng*h/ml at steady state.
Med uporabo 90 mg ticagrelorja je bila Cmax v stanju dinamičnega ravnovesja 627 ng/ml in AUC 6255 ng*h/ml.
For ticks effectiveness was between 85 and 93% for Broadline-treated cats compared with 92 and 98% for cats treated with the comparator product.
Pri klopih je bila učinkovitost zdravila Broadline od 85- do 93-odstotna v primerjavi z od 92- do 98-odstotno učinkovitostjo pri mačkah, zdravljenih s primerjalnim zdravilom.
For titration to 600 micrograms and 800 micrograms, tablets of 200 micrograms should be used.
Za titriranje do 600 mikrogramov in 800 mikrogramov se uporabljajo 200-mikrogramske tablete.
For tonsillitis or pharyngitis, between 84 and 92% of the patients taking Ketek, penicillin or clarithromycin had a satisfactory reduction in bacterial levels in samples taken from the throat.
Pri tonzilitisu ali faringitisu je bilo znižanje količin bakterij v vzorcih, ki so jih odvzeli iz grla, zadovoljivo pri 84–92 % bolnikov, ki so jemali zdravilo Ketek, penicilin ali klaritromicin.
For transmitters rated at a maximum output power not listed above, the recommended separation distance d in meters (m) can be estimated using the equation applicable to the frequency of the transmitter, where P is the maximum output power rating of the transmitter in watts (W) according to the transmitter manufacturer.
Za oddajnike ob največji moči oddajanja, ki zgoraj niso navedeni, se oceni priporočena razdalja d v metrih (m) z izračunom po enačbi za frekvenco oddajnikov, kjer je P po proizvajalčevi oceni njegova največja moč v wattih (W).
For transplanted patients in the Phase III studies, median time to neutrophil engraftment (10-11 days), median time to platelet engraftment (18-20 days) and graft durability up to 12 months post-transplantation were similar across the Mozobil and placebo groups.
V kliničnih študijah faze III. pri bolnikih s presadkom je bil v skupinah z zdravilom Mozobil in placebom podoben povprečni čas do vcepitve nevtrofilcev (10–11 dni), povprečni čas do vcepitve trombocitov (18–20 dni) in trajnost vcepitve do 12 mesecev po presaditvi.
For trastuzumab dose modifications, see trastuzumab summary of product characteristics.
Za odmerjanje in dajanje trastuzumaba prosimo, glejte povzetek glavnih značilnosti zdravila trastuzumaba.
For trastuzumab, dose reductions are not recommended, see trastuzumab summary of product characteristics (SmPC).
Odmerkov trastuzumaba ni priporočljivo zmanjševati; glejte Povzetek glavnih značilnosti zdravila trastuzumaba.
For treament of high blood pressure, the usual dose of Telmisartan Teva for most patients is 40 mg once a day to control your blood pressure over the 24-hour period.
Za zdravljenje visokega krvnega tlaka običajni odmerek zdravila Telmisartan Teva za doseganje urejenega krvnega tlaka v 24-urnem intervalu je pri večini bolnikov 40 mg enkrat dnevno.
For treating erectile dysfunction, the recommended dose of Cialis is 10 mg taken ‘on demand’ at least 30 minutes before sexual activity.
Priporočeni odmerek zdravila Cialis za zdravljenje erektilne disfunkcije je 10 mg, vzame pa se „po potrebi“ vsaj 30 minut pred spolno aktivnostjo.
For treating erectile dysfunction, the recommended dose of Tadalafil Mylan is 10 mg taken ‘on demand’ at least 30 minutes before sexual activity.
Za zdravljenje erektilne disfunkcije je priporočeni odmerek zdravila Tadalafil Mylan 10 mg, zaužit po potrebi, in sicer vsaj 30 minut pred spolno aktivnostjo.
for treating gout attacks
za zdravljenje napadov protina
for treating gout attacks or familial Mediterranean fever
pri protinu ali družinski mediteranski
For treating manic episodes in bipolar disorder, the recommended starting dose in adults is 15 mg by mouth once a day, either on its own or in combination with other medicines.
Za zdravljenje maničnih epizod pri bipolarni motnji je priporočeni začetni odmerek 15 mg peroralno enkrat na dan, samostojno ali v kombinaciji z drugimi zdravili.
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day.
Za zdravljenje maničnih epizod pri bolnikih, starih od 13 do 17 let, je začetni odmerek 2 mg na dan (pri čemer se uporablja zdravilo z aripiprazolom v tekoči obliki), ki se postopoma povečuje na priporočeni odmerek 10 mg enkrat na dan.
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day.
Za zdravljenje maničnih epizod pri bolnikih, starih od 13 do 17 let, se jemlje začetni odmerek 2 mg na dan (pri čemer se uporablja zdravilo z aripiprazolom v tekoči obliki), ki se postopoma povečuje na priporočeni odmerek 10 mg enkrat na dan.
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day, which is gradually increased to the recommended dose of 10 mg once a day.
Za zdravljenje maničnih epizod pri bolnikih, starih od 13 do 17 let, je začetni odmerek 2 mg na dan, ki se postopoma povečuje na priporočeni odmerek 10 mg enkrat na dan.
for treating non-union resulting from pathological (disease-related) fractures, metabolic bone disease or tumours.
za zdravljenje nezraslih zlomov, ki so nastali zaradi patoloških zlomov (povezanih z boleznimi), presnovnih bolezni kosti ali tumorjev;
for treatment
uporabljen za
For treatment after 3 weeks, the recommended dose is one 20 mg tablet once a day.
Po 3 tednih pa je priporočen odmerek ena tableta po 20 mg enkrat na dan.
For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent.
Za zdravljenje po neuspehu predhodne kemoterapije na podlagi platine je priporočeni odmerek 75 mg/m2 v monoterapiji.
For treatment and metaphylaxis of swine dysentery
Za zdravljenje in metafilakso dizeneterije pri prašičih
For treatment and metaphylaxis of swine dysentery
Za zdravljenje in metafilakso dizenterije pri prašičih
For treatment and metaphylaxis of swine dysentery:
Za zdravljenje in metafilakso dizenetrije pri prašičih